نتائج البحث - Dick C.G. Basart

  • يعرض 1 - 5 نتائج من 5
تنقيح النتائج
  1. 1
    Initial thyroid status and cardiovascular risk factors: The EPIC‐Norfolk prospective population study

    Initial thyroid status and cardiovascular risk factors: The EPIC‐Norfolk prospective population study حسب S. Matthijs Boekholdt, Sílvia M. Titan, Wilmar M. Wiersinga, Krishna Chatterjee, Dick C.G. Basart, Robert Luben, Nicholas J. Wareham, Kay‐Tee Khaw

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

    Efficacy of statins in familial hypercholesterolaemia: a long term cohort study حسب Jorie Versmissen, Daniëlla M. Oosterveer, Mojgan Yazdanpanah, Joep C. Defesche, Dick C.G. Basart, Anho Liem, Jan Heeringa, J. C. M. Witteman, Peter Lansberg, J.J.P. Kastelein, Eric J.G. Sijbrands

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

    Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-control... حسب Maartje E. Visser, Gilbert Wagener, Brenda F. Baker, Richard S. Geary, Joanne M. Donovan, Ulrich Beuers, Aart J. Nederveen, Joanne Verheij, Mieke D. Trip, Dick C.G. Basart, John J.P. Kastelein, Erik S.G. Stroes

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

    Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study حسب Erik S.G. Stroes, John R. Guyton, Norman E. Lepor, Fernando Civeira, Daniel Gaudet, Gerald F. Watts, Marie T. Baccara‐Dinet, Guillaume Lecorps, Garen Manvelian, Michel Farnier, Karam Kostner, Sam J. Lehman, Olivier Descamps, Lien Gheyle, Chantal Mathieu, Jean Bergeron, Tom Elliott, Gabriel Girard, Arpeta Gupta, Gordon Hoag, Jens D. Hove, Jørgen Jeppesen, J.H. Kjærulf, K. Klarlund, K.K. Thomsen, Dick C.G. Basart, Adriaan Kooy, Anho Liem, H. Swart, Roland P.T. Troquay, J Van Het Hof‐Wiersma, P. P. Viergever, Frank L.J. Visseren, Robert N. Doughty, Robert C. Scott, Carlos Calvo, José Luis Díaz-Díaz, Francisco Fuentes, Blas Gil Extremera, Carlos Rilova Jericó, Laia Matas Pericas, Juan Díaz García, D. Eric Bolster, Michael J. Koren, Mahfouz El Shahawy, Gil Vardi, D. Weinstein, K. Zuzarte, Henry N. Ginsberg, Jennifer G. Robinson, Daniel J. Rader, Christopher P. Cannon, Helen M. Colhoun, John J.P. Kastelein, Yong Huo, Anders Olsson, David D. Waters, Dominique Larrey, Robert S. Rosenson, P. Patriarca, Geert Molenberghs, Pierluigi Tricoci, Kenneth W. Mahaffey, Renato D. Lópes, Bimal R. Shah, Rajendra H. Mehta, Matthew T. Roe, Zubin J. Eapen, Luciana Armaganijan, Adriana Bertolami, Sergio Leonardi, Brad J. Kolls, J. Dedrick Jordan, Grégory Ducrocq, Étienne Puymirat, Robin Mathews

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease

    The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of th... حسب Salim Yusuf, S Mehta, Shuchi Anand, Álvaro Avezum, Najam A. Awan, M Bertrand, M Blumenthal, J. Bouthier, Andrzej Budaj, L Ceremuźyński, Susan Chrolavicius, J. Col, Patrick Commerford, Rubén Sierra Díaz, Marcus Flather, Kimberley Fox, Maria Grazia Franzosi, Christophe Gaudin, Bernard J. Gersh, W Grossman, David A. Halon, Timothy Hess, David Hunt, C. Joyner, N. B. Karatzas, Matyàs Keltai, Nardev S. Khurmi, Stephen L. Kopecky, B. Lewis, Aldo P. Maggioni, K. Malmberg, T. Mocceti, João Morais, Ernesto Paolasso, Ron J.G. Peters, Leopoldo Soares Piegas, Athanasios Pipilis, Marco Antonio Ramos-Corrales, H.-J. Rupprecht, Lars Rydén, E Sitkei, M. Sotty, Gianni Tognoni, V. Valentin, George Varigos, Petr Widimský, Thomas Wittlinger, Janice Pogue, Ingrid Copland, B. Cracknell, Catherine Demers, John W. Eikelboom, K. V. Hall, J. Keys, Matthew B. McQueen, Patricia Montague, Beth Morris, Stephanie Ôunpuu, Christine Wright, Vince Yacyshyn, Feng Zhao, Basil S. Lewis, Patrick Commerford, George Wyse, J. Cairns, Robert G. Hart, J. Hirsh, Michael Gent, Timothy Ryan, Janet Wittes, Pierre Auger, Dick C.G. Basart, Y.C. Chan, Herbert De Raedt, M. Den Hartoog, Manuela Galli, Javier García-Guerrero, J. Marquis, Francesco Mauri, Bongani M. Mayosi, Madhu K. Natarajan, Melina Nieminen-Kelhä, John W. Norris, Akbar Panju, Ron J.G. Peters, Jean Renkin, C. Rihal, Piotr Szymański, Wojciech Wąsek, Guillermo Einer Allende, Julio Bono, Alberto Caccavo, Andres Fernandez, Juan J. Fuselli, A. J. Gambarte, R. A. Ahuad Guerrero, Eduardo Hasbani, Álvaro Sosa Liprandi

    منشور في 2000
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: